David J. McConkey
YOU?
Author Swipe
View article: T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer
T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer Open
Background Bladder cancer is unique among visceral malignancies in that urine, which can be easily obtained, has prolonged contact with bladder tumors. Urinary biomarkers offer the potential to provide insight into the host and tumor immun…
View article: Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer
Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer Open
Multiplatform mutational and gene expression profiling complemented with proteomic and metabolomic spatial mapping were used on the whole‐organ scale to identify the molecular profile of bladder cancer evolution from field effects. Analysi…
View article: Table 2 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Table 2 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Autoantibody presence at baseline in patients in cohorts A (n = 6) and B (n = 23) with vs. without EVDEs and in patients with EVDEs requiring intervention.
View article: Table 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Table 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Baseline characteristics of patients with vs. without EVDEs (cohort B).
View article: Data from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Data from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Enfortumab vedotin (EV) plus pembrolizumab (P) is the first-line treatment for patients with advanced urothelial cancer (aUC). No biomarker for EV toxicity or response has been prospectively validated. EV-related dermatologic events (EVDE)…
View article: Supplementary Table 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Supplementary Table 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Table 1
View article: Supplementary Table 2 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Supplementary Table 2 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Table 2
View article: Supplementary Table 5 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Supplementary Table 5 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Table 5
View article: Supplementary Table 4 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Supplementary Table 4 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Table 4
View article: Supplementary Figure 2 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Supplementary Figure 2 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Figure 2
View article: Figure 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Figure 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
IPs from radiolabeled cell extracts using the pilot cohort sera (A), and validation of ROCK2 (B) and TOM1L1 (C) antibodies in the index sera. A, IPs were performed using 35S-methionine–labeled MCF7 ce…
View article: Supplementary Figure 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Supplementary Figure 1 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Figure 1
View article: Table 3 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Table 3 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Radiographic response in cohort B patients with vs. without EVDEs (n = 23).
View article: Supplementary Table 3 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Supplementary Table 3 from Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Table 3
View article: Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer
Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer Open
Enfortumab vedotin (EV) plus pembrolizumab (P) is the first-line treatment for patients with advanced urothelial cancer (aUC). No biomarker for EV toxicity or response has been prospectively validated. EV-related dermatologic events (EVDE)…
View article: Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review
Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review Open
View article: Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning Open
Building accurate prediction models and identifying predictive biomarkers for treatment response in Muscle-Invasive Bladder Cancer (MIBC) are essential for improving patient survival but remain challenging due to tumor heterogeneity, despi…
View article: Sarcomatoid areas of urothelial carcinoma are enriched for <scp>CD163</scp>‐positive antigen‐presenting cells
Sarcomatoid areas of urothelial carcinoma are enriched for <span>CD163</span>‐positive antigen‐presenting cells Open
Sarcomatoid urothelial carcinoma (SUC) is a rare histologic subtype with poor prognosis. While there is known intra‐tumoral heterogeneity between individual SUC tumors, the relationship between sarcomatoid and conventional urothelial carci…
View article: Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.
Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery. Open
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on their gene e…
View article: Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer <sup/>
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer <sup/> Open
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)’ led by the Bladder Canc…
View article: NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA
NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA Open
The optimization of dosing strategies is critical for maximizing efficacy and minimizing toxicity in drug development, particularly for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study demonstrates …
View article: YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation
YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation Open
The Hippo signaling pathway plays a key role in tumorigenesis in different cancer types. We investigated the role of the Hippo effector YAP1 in the tumor immune microenvironment (TIME) of urothelial carcinoma of the bladder (UCB) and evalu…
View article: Heterogeneous Effects of Src Inhibition on Determinants of Metastasis in Preclinical Models of Human Bladder Cancer
Heterogeneous Effects of Src Inhibition on Determinants of Metastasis in Preclinical Models of Human Bladder Cancer Open
Background Past work in preclinical models of solid tumors have implicated SRC in invasion and metastasis, but also demonstrated it inhibited bladder cancer metastasis. Objective Determine if the role of SRC in metastasis is dependent on b…
View article: Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model Open
Introduction Nadofaragene firadenovec (Ad-IFNα/Syn3) is now approved for BCG-unresponsive bladder cancer (BLCA). IFNα is a pleiotropic cytokine that causes direct tumor cell killing via TRAIL-mediated apoptosis, angiogenesis inhibition, an…
View article: Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec Open
By analyzing urine-borne tumor DNA, we can help determine which patients with high-grade non-muscle-invasive bladder cancer are at the greatest risk of recurrence when receiving second-line therapy.
View article: Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer Open
Importance In metastatic hormone-sensitive prostate cancer (mHSPC), new first-line combination therapies have enhanced overall survival (OS), but clinical outcomes for individual patients vary greatly and are difficult to predict. Peripher…
View article: Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer Open
Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects of rosiglitazone, Pparg agoni…
View article: Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience
Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience Open
Introduction Enfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4. No validated biomarker pr…
View article: Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis Open
BACKGROUND: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. OBJECTIVE: We evaluated the clinical activity and safety of neoadjuvant cisplatin plus gem…
View article: The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward Open
BACKGROUND: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene therapy developed f…